Proactive Investors - Run By Investors For Investors

Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer

The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders.
Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer
Paradigm’s board thanked shareholders for their support of the entitlement offer

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has raised about $16.15 million at $1.50 per share, completing the retail component of its one-for-eight accelerated non-renounceable entitlement offer.

The retail entitlement offer, which is fully underwritten by Bell Potter Solutions Limited, closed on May 6, 2019 and together with shares issued under the institutional component of the entitlement offer, the total amount raised will be about $26.3 million.

READ: Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer

The shortfall under the entitlement offer will rank equally with existing shares on issue.

Shares issues under the retail entitlement offer are expected to be issued on May 13, 2019 and will be allotted and quoted on the ASX on May 14, 2019.

Last Month Paradigm completed the institutional component of the fully underwritten accelerated non-renounceable entitlement offer raising about $9.8 million.

The new funds will allow the company to advance its pivotal phase 3 OA clinical trial in the US, EU and Australia as well as to complete the phase 2/3 pivotal clinical trial in MPS.

View full PAR profile View Profile

Paradigm Biopharmaceuticals Ltd Timeline

Related Articles

June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
picture of a knee
May 20 2019
We take a closer look at Collagen Solutions, which received third-party validation of its business model in the form of outside investment from a blue-chip US agriculture company
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use